Hydrocarbons, Fluorinated
"Hydrocarbons, Fluorinated" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inert liquid or gaseous halocarbon compounds in which FLUORINE replaces some or all HYDROGEN atoms.
| Descriptor ID |
D006845
|
| MeSH Number(s) |
D02.455.526.510
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrocarbons, Fluorinated".
Below are MeSH descriptors whose meaning is more specific than "Hydrocarbons, Fluorinated".
This graph shows the total number of publications written about "Hydrocarbons, Fluorinated" by people in this website by year, and whether "Hydrocarbons, Fluorinated" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2009 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydrocarbons, Fluorinated" by people in Profiles.
-
Reduction of Heavy Menstrual Bleeding in Women Not Designated as Responders to Elagolix Plus Add Back Therapy for Uterine Fibroids. J Womens Health (Larchmt). 2022 05; 31(5):698-705.
-
Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas. Obstet Gynecol. 2020 06; 135(6):1313-1326.
-
Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids. N Engl J Med. 2020 01 23; 382(4):328-340.
-
Elagolix Alone or With Add-Back Therapy in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas: A Randomized Controlled Trial. Obstet Gynecol. 2018 11; 132(5):1252-1264.
-
SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget. 2016 Oct 25; 7(43):69321-69336.
-
Reply: Pharmacokinetic and Pharmacodynamic Modifiers of EF5 Uptake and Binding. J Nucl Med. 2015 Apr; 56(4):653-4.
-
Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models. J Nucl Med. 2014 Jul; 55(7):1192-7.
-
18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. J Nucl Med. 2013 Aug; 54(8):1339-46.
-
A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5). Nucl Med Biol. 2012 Oct; 39(7):1012-8.
-
Liver X receptor agonists augment human islet function through activation of anaplerotic pathways and glycerolipid/free fatty acid cycling. J Biol Chem. 2010 Feb 19; 285(8):5392-404.